YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease

Yongzhong Wang, Rasmus Sejersten Ripa, Julia Sidenius Johansen, Anders Gabrielsen, Daniel A Steinbruchel, Tina Friis, Lene Bindslev, Mandana Haack-Sørensen, Erik Jørgensen, Jens Kastrup

Abstract

BACKGROUND: YKL-40 is involved in remodelling and angiogenesis in non-cardiac inflammatory diseases. Aim was to quantitate plasma YKL-40 in patients with ST-elevation myocardial infarction (STEMI) or stable chronic coronary artery disease (CAD), and YKL-40 gene activation in human myocardium.

METHODS AND RESULTS: We included 73 patients: I) 20 patients with STEMI; II) 28 patients with stable CAD; III) 15 CAD patients referred for coronary by-pass surgery. YKL-40 mRNA expression was measured in myocardium subtended by stenotic or occluded arteries and areas with no apparent disease; and IV) 10 age-matched healthy controls. Plasma YKL-40 was significantly increased in patients with STEMI (88 microg/l, median) and CAD (66 microg/l) compared to controls (16 microg/l, p<0.01 for both). Plasma YKL-40 correlated with CRP at baseline in STEMI (r=0.53, p=0.02) and CAD patients (r=0.41, p=0.031).YKL-40 gene expression was similar in ischemic and non-ischemic myocardium.

CONCLUSIONS: Plasma YKL-40 was significantly increased in patients with STEMI and stable CAD. Further studies will define the role of YKL-40 as a clinically useful marker for myocardial ischemia, remodelling and maybe prognosis.

OriginalsprogEngelsk
TidsskriftScandinavian cardiovascular journal : SCJ
Vol/bind42
Udgave nummer5
Sider (fra-til)295-302
Antal sider8
ISSN1401-7431
DOI
StatusUdgivet - okt. 2008

Fingeraftryk

Dyk ned i forskningsemnerne om 'YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease'. Sammen danner de et unikt fingeraftryk.

Citationsformater